Management of chronic obstructive pulmonary disease beyond the lungs

The Lancet Respiratory Medicine

Volumn 4, Issue 11, 2016, Pages 911-924

  Vanfleteren, Lowie E G W ^a,b   Spruit, Martijn A ^a   Wouters, Emiel F M ^a,b   Franssen, Frits M E ^a,b  

^a Centre of Expertise for Chronic Organ Failure   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BOSENTAN; CARVEDILOL; CELIPROLOL; CLOPIDOGREL; CORTICOSTEROID DERIVATIVE; DAPAGLIFLOZIN; DEXMEDETOMIDINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; INSULIN; LANSOPRAZOLE; LOSARTAN; METFORMIN; METOPROLOL; MORPHINE; PLACEBO; PROTON PUMP INHIBITOR; ROFLUMILAST; SIMVASTATIN; TADALAFIL; TICAGRELOR; UNINDEXED DRUG; VITAMIN D;

ANXIETY; ASTHMA; BODY MASS; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL RESEARCH; COMMON COLD; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DYSPNEA; GASTROESOPHAGEAL REFLUX; HEART DISEASE; HEART FAILURE; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MENTAL DISEASE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OSTEOPOROSIS; PARALLEL DESIGN; PATIENT COUNSELING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SMOKING CESSATION; TELEMONITORING; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY; WEIGHT REDUCTION; COMPLICATION; DISEASE MANAGEMENT;

CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; DISEASE PROGRESSION; DYSPNEA; GASTROESOPHAGEAL REFLUX; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84971607470     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)00097-7     Document Type: Review

References (104)

1. 1 Vanfleteren, LE, Spruit, MA, Groenen, M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 187 (2013), 728–735.
2. 2 Gottlieb, SS, McCarter, RJ, Vogel, RA, Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339 (1998), 489–497.
3. 3 Han, MK, Agusti, A, Calverley, PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 182 (2010), 598–604.
4. 4 Vestbo, J, Hurd, SS, Agustí, AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187 (2013), 347–365.
5. 5 Divo, MJ, Casanova, C, Marin, JM, et al. COPD comorbidities network. Eur Respir J 46 (2015), 640–650.
6. 6 Woodruff, PG, Agusti, A, Roche, N, Singh, D, Martinez, FJ, Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet 385 (2015), 1789–1798.
7. 7 Triest, FJ, Franssen, FM, Spruit, MA, Groenen, MT, Wouters, EF, Vanfleteren, LE, Poor agreement between chart-based and objectively identified comorbidities of COPD. Eur Respir J 46 (2015), 1492–1495.
8. 8 Freixa, X, Portillo, K, Pare, C, et al. Echocardiographic abnormalities in patients with COPD at their first hospital admission. Eur Respir J 41 (2013), 784–791.
9. 9 Vanfleteren, LE, Franssen, FM, Uszko-Lencer, NH, et al. Frequency and relevance of ischemic electrocardiographic findings in patients with chronic obstructive pulmonary disease. Am J Cardiol 108 (2011), 1669–1674.
10. 10 Macchia, A, Rodriguez Moncalvo, JJ, Kleinert, M, et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J 39 (2012), 51–58.
11. 11 Watz, H, Waschki, B, Kirsten, A, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 136 (2009), 1039–1046.
12. 12 Barr, RG, Ahmed, FS, Carr, JJ, et al. Subclinical atherosclerosis, airflow obstruction and emphysema: the MESA Lung Study. Eur Respir J 39 (2012), 846–854.
13. 13 Barr, RG, Mesia-Vela, S, Austin, JH, et al. Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. Am J Respir Crit Care Med 176 (2007), 1200–1207.
14. 14 McAllister, DA, Maclay, JD, Mills, NL, et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176 (2007), 1208–1214.
15. 15 Clarenbach, CF, Sievi, NA, Brock, M, Schneiter, D, Weder, W, Kohler, M, Lung volume reduction surgery and improvement of endothelial function and blood pressure in patients with chronic obstructive pulmonary disease. A randomized controlled trial. Am J Respir Crit Care Med 192 (2015), 307–314.
16. 16 MacDonald, MI, Shafuddin, E, King, PT, Chang, CL, Bardin, PG, Hancox, RJ, Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med 4 (2016), 138–148.
17. 17 van der Woude, HJ, Zaagsma, J, Postma, DS, Winter, TH, van Hulst, M, Aalbers, R, Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest 127 (2005), 818–824.
18. 18 Au, DH, Bryson, CL, Fan, VS, et al. Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med 117 (2004), 925–931.
19. 19 Rutten, FH, Zuithoff, NP, Hak, E, Grobbee, DE, Hoes, AW, Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 170 (2010), 880–887.
20. 20 Short, PM, Lipworth, SI, Elder, DH, Schembri, S, Lipworth, BJ, Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ, 342, 2011, d2549.
21. 21 Dransfield, MT, Rowe, SM, Johnson, JE, Bailey, WC, Gerald, LB, Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 63 (2008), 301–305.
22. 22 Stefan, MS, Rothberg, MB, Priya, A, Pekow, PS, Au, DH, Lindenauer, PK, Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 67 (2012), 977–984.
23. 23 Chhabra, SK, Gupta, M, Ramaswamy, S, Dash, DJ, Bansal, V, Deepak, KK, Cardiac sympathetic dominance and systemic inflammation in COPD. COPD 12 (2015), 552–559.
24. 24 Warnier, MJ, Rutten, FH, de Boer, A, Hoes, AW, De Bruin, ML, Resting heart rate is a risk factor for mortality in chronic obstructive pulmonary disease, but not for exacerbations or pneumonia. PLoS One, 9, 2014, e105152.
25. 25 Lahousse, L, Verhamme, KM, Stricker, BH, Brusselle, GG, Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir Med 4 (2016), 149–164.
26. 26 Au, DH, Udris, EM, Fan, VS, Curtis, JR, McDonell, MB, Fihn, SD, Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 123 (2003), 1964–1969.
27. 27 Buajordet, I, Ebbesen, J, Erikssen, J, Brørs, O, Hilberg, T, Fatal adverse drug events: the paradox of drug treatment. J Intern Med 250 (2001), 327–341.
28. 28 Morales, DR, Jackson, C, Lipworth, BJ, Donnan, PT, Guthrie, B, Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest 145 (2014), 779–786.
29. 29 Chang, CL, Mills, GD, McLachlan, JD, Karalus, NC, Hancox, RJ, Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Intern Med J 40 (2010), 193–200.
30. 30 Mancini, GB, Etminan, M, Zhang, B, Levesque, LE, FitzGerald, JM, Brophy, JM, Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 47 (2006), 2554–2560.
31. 31 Horita, N, Miyazawa, N, Kojima, R, et al. Statins reduce all-cause mortality in chronic obstructive pulmonary disease: a systematic review and meta-analysis of observational studies. Respir Res, 15, 2014, 80.
32. 32 Wang, MT, Lo, YW, Tsai, CL, et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med 126 (2013), 598–606 e2.
33. 33 van Gestel, YR, Hoeks, SE, Sin, DD, et al. COPD and cancer mortality: the influence of statins. Thorax 64 (2009), 963–967.
34. 34 Criner, GJ, Connett, JE, Aaron, SD, et al. the COPD Clinical Research Network, the Canadian Institutes of Health Research. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 370 (2014), 2201–2210.
35. 35 Harrison, MT, Short, P, Williamson, PA, Singanayagam, A, Chalmers, JD, Schembri, S, Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy?. Thorax 69 (2014), 609–615.
36. 36 Sin, DD, The devastating power of platelets in COPD exacerbations: can aspirin save lives in COPD?. Thorax 69 (2014), 603–604.
37. 37 Maclay, JD, McAllister, DA, Johnston, S, et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 66 (2011), 769–774.
38. 38 Thirapatarapong, W, Armstrong, HF, Bartels, MN, Comparing cardiopulmonary exercise testing in severe COPD patients with and without pulmonary hypertension. Heart Lung Circ 23 (2014), 833–840.
39. 39 Goudie, AR, Lipworth, BJ, Hopkinson, PJ, Wei, L, Struthers, AD, Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 2 (2014), 293–300.
40. 40 Breyer, MK, Spruit, MA, Hanson, CK, et al. Prevalence of metabolic syndrome in COPD patients and its consequences. PLoS One, 9, 2014, e98013.
41. 41 Islam, EA, Limsuwat, C, Nantsupawat, T, Berdine, GG, Nugent, KM, The association between glucose levels and hospital outcomes in patients with acute exacerbations of chronic obstructive pulmonary disease. Ann Thorac Med 10 (2015), 94–99.
42. 42 Hitchings, AW, Lai, D, Jones, PW, Baker, EH, Metformin in CTT. Metformin in severe exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial. Thorax, 2016, 10.1136/thoraxjnl-2015-208035 published online Feb 25.
43. 43 van den Borst, B, Gosker, HR, Zeegers, MP, Schols, AM, Pulmonary function in diabetes: a metaanalysis. Chest 138 (2010), 393–406.
44. 44 Sexton, P, Metcalf, P, Kolbe, J, Respiratory effects of insulin sensitisation with metformin: a prospective observational study. COPD 11 (2014), 133–142.
45. 45 Fabbri, LM, Calverley, PM, Izquierdo-Alonso, JL, et al., the M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374 (2009), 695–703.
46. 46 Martinez, FJ, Calverley, PM, Goehring, UM, Brose, M, Fabbri, LM, Rabe, KF, Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 385 (2015), 857–866.
47. 47 Wouters, EF, Bredenbröker, D, Teichmann, P, et al. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab 97 (2012), E1720–E1725.
48. 48 Vermeeren, MA, Creutzberg, EC, Schols, AM, et al., the COSMIC Study Group. Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med 100 (2006), 1349–1355.
49. 49 Sahebjami, H, Doers, JT, Render, ML, Bond, TL, Anthropometric and pulmonary function test profiles of outpatients with stable chronic obstructive pulmonary disease. Am J Med 94 (1993), 469–474.
50. 50 Wilson, DO, Rogers, RM, Wright, EC, Anthonisen, NR, Body weight in chronic obstructive pulmonary disease: the National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir Dis 139 (1989), 1435–1438.
51. 51 van den Borst, B, Koster, A, Yu, B, et al. Is age-related decline in lean mass and physical function accelerated by obstructive lung disease or smoking?. Thorax 66 (2011), 961–969.
52. 52 Schols, AM, Slangen, J, Volovics, L, Wouters, EF, Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157 (1998), 1791–1797.
53. 53 Ferreira, IM, Brooks, D, White, J, Goldstein, R, Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 12, 2012 CD000998.
54. 54 Vestbo, J, Prescott, E, Almdal, T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 173 (2006), 79–83.
55. 55 Pan, L, Wang, M, Xie, X, Du, C, Guo, Y, Effects of anabolic steroids on chronic obstructive pulmonary disease: a meta-analysis of randomised controlled trials. PLoS One, 9, 2014, e84855.
56. 56 Casaburi, R, Bhasin, S, Cosentino, L, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170 (2004), 870–878.
57. 57 Cecere, LM, Littman, AJ, Slatore, CG, et al. Obesity and COPD: associated symptoms, health-related quality of life, and medication use. COPD 8 (2011), 275–284.
58. 58 Bautista, J, Ehsan, M, Normandin, E, Zuwallack, R, Lahiri, B, Physiologic responses during the six minute walk test in obese and non-obese COPD patients. Respir Med 105 (2011), 1189–1194.
59. 59 Maatman, RC, Spruit, MA, van Melick, PP, et al. Effects of obesity on weight-bearing versus weight-supported exercise testing in patients with COPD. Respirology 21 (2016), 483–488.
60. 60 O'Donnell, DE, Deesomchok, A, Lam, YM, et al. Effects of body mass index on static lung volumes in patients with airway obstruction. Chest 140 (2011), 461–468.
61. 61 Landbo, C, Prescott, E, Lange, P, Vestbo, J, Almdal, TP, Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160 (1999), 1856–1861.
62. 62 Agustí, A, Edwards, LD, Rennard, SI, et al., the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One, 7, 2012, e37483.
63. 63 Vanfleteren, LE, van Meerendonk, AM, Franssen, FM, et al. A possible link between increased metabolic activity of fat tissue and aortic wall inflammation in subjects with COPD. A retrospective 18F-FDG-PET/CT pilot study. Respir Med 108 (2014), 883–890.
64. 64 Sava, F, Laviolette, L, Bernard, S, Breton, MJ, Bourbeau, J, Maltais, F, The impact of obesity on walking and cycling performance and response to pulmonary rehabilitation in COPD. BMC Pulm Med, 10, 2010, 55.
65. 65 McNamara, RJ, McKeough, ZJ, McKenzie, DK, Alison, JA, Water-based exercise in COPD with physical comorbidities: a randomised controlled trial. Eur Respir J 41 (2013), 1284–1291.
66. 66 Spruit, MA, Singh, SJ, Garvey, C, et al., the ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 188 (2013), e13–e64.
67. 67 Chong, J, Leung, B, Poole, P, Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 11, 2013 CD002309.
68. 68 Graat-Verboom, L, van den Borne, BE, Smeenk, FW, Spruit, MA, Wouters, EF, Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures. J Bone Miner Res 26 (2011), 561–568.
69. 69 Carter, JD, Patel, S, Sultan, FL, et al. The recognition and treatment of vertebral fractures in males with chronic obstructive pulmonary disease. Respir Med 102 (2008), 1165–1172.
70. 70 Barrett-Connor, E, Nielson, CM, Orwoll, E, Bauer, DC, Cauley, JA, the Osteoporotic Fractures in Men Study Group. Epidemiology of rib fractures in older men: Osteoporotic Fractures in Men (MrOS) prospective cohort study. BMJ, 340, 2010, c1069.
71. 71 Regan, EA, Radcliff, TA, Henderson, WG, et al. Improving hip fractures outcomes for COPD patients. COPD 10 (2013), 11–19.
72. 72 Lehouck, A, Boonen, S, Decramer, M, Janssens, W, COPD, bone metabolism, and osteoporosis. Chest 139 (2011), 648–657.
73. 73 Richtlijn Osteoporose en Fractuurpreventie derde herziening. www.diliguide.nl/document/1015, 2011 (accessed April 26, 2016; in Dutch).
74. 74 Jolliffe, DA, Griffiths, CJ, Martineau, AR, Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies. J Steroid Biochem Mol Biol 136 (2013), 321–329.
75. 75 Skaaby, T, Husemoen, LL, Thuesen, BH, et al. Vitamin D status and chronic obstructive pulmonary disease: a prospective general population study. PLoS One, 9, 2014, e90654.
76. 76 Lehouck, A, Mathieu, C, Carremans, C, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 156 (2012), 105–114.
77. 77 Martineau, AR, James, WY, Hooper, RL, et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 3 (2015), 120–130.
78. 78 Casanova, C, Baudet, JS, del Valle Velasco, M, et al. Increased gastro-oesophageal reflux disease in patients with severe COPD. Eur Respir J 23 (2004), 841–845.
79. 79 Rascon-Aguilar, IE, Pamer, M, Wludyka, P, et al. Role of gastroesophageal reflux symptoms in exacerbations of COPD. Chest 130 (2006), 1096–1101.
80. 80 Hurst, JR, Vestbo, J, Anzueto, A, et al., the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363 (2010), 1128–1138.
81. 81 Crowell, MD, Zayat, EN, Lacy, BE, Schettler-Duncan, A, Liu, MC, The effects of an inhaled beta(2)-adrenergic agonist on lower esophageal function: a dose-response study. Chest 120 (2001), 1184–1189.
82. 82 Sasaki, T, Nakayama, K, Yasuda, H, et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. J Am Geriatr Soc 57 (2009), 1453–1457.
83. 83 Becker, JC, Grosser, N, Waltke, C, et al. Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun 345 (2006), 1014–1021.
84. 84 Vögele, C, von Leupoldt, A, Mental disorders in chronic obstructive pulmonary disease (COPD). Respir Med 102 (2008), 764–773.
85. 85 Smoller, JW, Pollack, MH, Otto, MW, Rosenbaum, JF, Kradin, RL, Panic anxiety, dyspnea, and respiratory disease. Theoretical and clinical considerations. Am J Respir Crit Care Med 154 (1996), 6–17.
86. 86 Howard, C, Dupont, S, Haselden, B, Lynch, J, Wills, P, The effectiveness of a group cognitive-behavioural breathlessness intervention on health status, mood and hospital admissions in elderly patients with chronic obstructive pulmonary disease. Psychol Health Med 15 (2010), 371–385.
87. 87 Jennings, AL, Davies, AN, Higgins, JP, Gibbs, JS, Broadley, KE, A systematic review of the use of opioids in the management of dyspnoea. Thorax 57 (2002), 939–944.
88. 88 Ekström, MP, Bornefalk-Hermansson, A, Abernethy, AP, Currow, DC, Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ, 348, 2014, g445.
89. 89 Hegerl, U, Mergl, R, Depression and suicidality in COPD: understandable reaction or independent disorders?. Eur Respir J 44 (2014), 734–743.
90. 90 Zigmond, AS, Snaith, RP, The hospital anxiety and depression scale. Acta Psychiatr Scand 67 (1983), 361–370.
91. 91 Spruit, MA, Augustin, IM, Vanfleteren, LE, et al., the CIRO+ Rehabilitation Network. Differential response to pulmonary rehabilitation in COPD: multidimensional profiling. Eur Respir J 46 (2015), 1625–1635.
92. 92 Fritzsche, A, Clamor, A, von Leupoldt, A, Effects of medical and psychological treatment of depression in patients with COPD—a review. Respir Med 105 (2011), 1422–1433.
93. 93 Wagena, EJ, Knipschild, PG, Huibers, MJ, Wouters, EF, van Schayck, CP, Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med 165 (2005), 2286–2292.
94. 94 Spruit, MA, Pitta, F, McAuley, E, ZuWallack, RL, Nici, L, Pulmonary rehabilitation and physical activity in patients with COPD. Am J Respir Crit Care Med 192 (2015), 924–933.
95. 95 Mesquita, R, Vanfleteren, LE, Franssen, FM, et al. Objectively identified comorbidities in chronic obstructive pulmonary disease: impact on pulmonary rehabilitation outcomes. Eur Respir J 46 (2015), 545–548.
96. 96 Harrison, SL, Greening, NJ, Williams, JE, Morgan, MD, Steiner, MC, Singh, SJ, Have we underestimated the efficacy of pulmonary rehabilitation in improving mood?. Respir Med 106 (2012), 838–844.
97. 97 Franssen, FM, Broekhuizen, R, Janssen, PP, Wouters, EF, Schols, AM, Effects of whole-body exercise training on body composition and functional capacity in normal-weight patients with COPD. Chest 125 (2004), 2021–2028.
98. 98 Vanfleteren, LE, Spruit, MA, Groenen, MT, et al. Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation. Eur Respir J 43 (2014), 1306–1315.
99. 99 Gale, NS, Duckers, JM, Enright, S, Cockcroft, JR, Shale, DJ, Bolton, CE, Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD?. BMC Pulm Med, 11, 2011, 20.
100. 100 Agusti, A, The path to personalised medicine in COPD. Thorax 69 (2014), 857–864.
101. 101 Schols, AM, Ferreira, IM, Franssen, FM, et al. Nutritional assessment and therapy in COPD: a European Respiratory Society statement. Eur Respir J 44 (2014), 1504–1520.
102. 102 Garcia-Aymerich, J, Gómez, FP, Benet, M, et al., the PAC-COPD Study Group. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 66 (2011), 430–437.
103. 103 Bon, J, Fuhrman, CR, Weissfeld, JL, et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med 183 (2011), 885–890.
104. 104 Lötvall, J, Akdis, CA, Bacharier, LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 127 (2011), 355–360.